The rLVS Δ capB / iglABC vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent Francisella tularensis strains
Authors:
Open Access
- 17 November 2023
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (3) , 2277083
Abstract
Francisella tularensis is one of the several biothreat agents for which a licensed vaccine is needed. To ensure vaccine protection is achieved across a range of virulent F. tularensis strains, we assembled and characterized a panel of F. tularensis isolates to be utilized as challenge strains. A promising tularemia vaccine candidate is rLVS ΔcapB/iglABC (rLVS), in which the vector is the LVS strain with a deletion in the capB gene and which additionally expresses a fusion protein comprising immunodominant epitopes of proteins IglA, IglB, and IglC. Fischer rats were immunized subcutaneously 1-3 times at 3-week intervals with rLVS at various doses. The rats were exposed to a high dose of aerosolized Type A strain Schu S4 (FRAN244), a Type B strain (FRAN255), or a tick derived Type A strain (FRAN254) and monitored for survival. All rLVS vaccination regimens including a single dose of 107 CFU rLVS provided 100% protection against both Type A strains. Against the Type B strain, two doses of 107 CFU rLVS provided 100% protection, and a single dose of 107 CFU provided 87.5% protection. In contrast, all unvaccinated rats succumbed to aerosol challenge with all of the F. tularensis strains. A robust Th1-biased antibody response was induced in all vaccinated rats against all F. tularensis strains. These results demonstrate that rLVS ΔcapB/iglABC provides potent protection against inhalational challenge with either Type A or Type B F. tularensis strains and should be considered for further analysis as a future tularemia vaccine.Keywords
Funding Information
- Defense Threat Reduction Agency (CB10477)
This publication has 67 references indexed in Scilit:
- Antibodies Contribute to Effective Vaccination against Respiratory Infection by Type AFrancisella tularensisStrainsInfection and Immunity, 2011
- A Francisella tularensis Live Vaccine Strain (LVS) Mutant with a Deletion in capB , Encoding a Putative Capsular Biosynthesis Protein, Is Significantly More Attenuated than LVS yet Induces Potent Protective Immunity in Mice against F. tularensis ChallengeInfection and Immunity, 2010
- Reintroduction of Two Deleted Virulence Loci Restores Full Virulence to the Live Vaccine Strain of Francisella tularensisInfection and Immunity, 2009
- Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strainsVaccine, 2009
- Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus)International Journal of Experimental Pathology, 2009
- Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensisVaccine, 2009
- Identification of an Essential Francisella tularensis subsp. tularensis Virulence FactorInfection and Immunity, 2009
- An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strainVaccine, 2008
- An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routesVaccine, 2008
- Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strainsGenome Biology, 2007